New Jersey is currently home to 1712 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
FirmTech User Research Trial
Recruiting
The objective of this study is to see whether a home-use penile constriction device, Firmtech Tech Ring, can be determined to be superior to the Giddy device through evaluation of Leikert scale scores to assess ease of use and participant comfort and satisfaction with erectile quality with these devices. The primary outcome will be the satisfaction with use of the device as assessed through the Leikert scores. The other outcomes will be secondary.
Gender:
Male
Ages:
Between 18 years and 70 years
Trial Updated:
05/02/2023
Locations: IVI RMA New Jersey, Basking Ridge, New Jersey
Conditions: Erectile Function
Exercise and Time of Day in Type 2 Diabetes
Recruiting
The overall purpose of the study is to test the effect of Noom on exercise and diet advice in adults with type 2 diabetes. The overarching hypothesis is that the use of Noom may promote better dietary adherence during an exercise program, thereby promoting greater weight loss and cardiometabolic health compared to lifestyle advice only. In particular, the investigators anticipate that changes in metabolic and vascular insulin sensitivity will correlate with glycemic control and blood pressure ch... Read More
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
05/02/2023
Locations: New Jersey Institute for Food, Nutrition, and Health, New Brunswick, New Jersey
Conditions: Diabetes Mellitus, Type 2, Metabolic Syndrome
Discarded Materials Study
Recruiting
Use of discarded embryos to advance laboratory expertise and technology in the area of human embryo development and assisted reproductive technologies
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2023
Locations: Reproductive Medicine Associates of new Jersey, Basking Ridge, New Jersey
Conditions: Infertility
Neurofeedback Intervention for Reading Deficits in Subacute Stroke
Recruiting
The overall goal of this project is to advance a biologically-based approach to treatment of reading disorders after stroke, which will expand the limits of cognitive rehabilitation. Using a novel brain imaging technique, called real-time functional magnetic resonance imaging (fMRI) neurofeedback combined with right hand motor imagery, this project will re-instate brain activity in the left language-dominant hemisphere. Stroke patients will practice modulating their own brain activity using fMRI... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/01/2023
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Stroke, Dyslexia, Acquired
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Recruiting
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Gender:
All
Ages:
17 years and below
Trial Updated:
05/01/2023
Locations: Bristol-Myers Squibb, Active, Princeton, New Jersey
Conditions: Juvenile Idiopathic Arthritis
Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma
Recruiting
This study will use a systematic music therapy intervention on patients with mental illness trying to help them with their internalized stigma.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2023
Locations: Carrier Clinic, Belle Mead, New Jersey
Conditions: Mental Health Issues, Bipolar Disorder, Depressive, Schizophrenia Spectrum and Other Psychotic Disorders, Anxiety Disorder
Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study
Recruiting
To examine in Arista hemostatic powder results in less post-total knee arthroplasty blood loss, hematoma formation, and improved range of motion when compared to patients who did not receive the product.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2023
Locations: Virtua Health System, Marlton, New Jersey
Conditions: Blood Loss, Surgical
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
Recruiting
Approximately 90 patients, aged 50 to 80 years, with a diagnosis of early Alzheimer's disease will take part in this research study. This study will be conducted in the US. There will be 3 treatment groups: 2 Active doses and 1 group will receive placebo completely by chance. Patients, caregiver, Sponsor, nor study staff will know which treatment is assigned. There are 3 periods in this study: Screening to confirm suitability, Treatment to receive study medication, and Follow-up to check overall... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/23/2023
Locations: Advanced Clinical Institute Inc, Neptune, New Jersey
Conditions: Alzheimer's Disease
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
Recruiting
This phase II trial investigates the safety of delivering a part (boost) of radiation treatment before breast surgery in treating patients with breast cancer that has not spread to other places in the body (non-metastatic). Radiation therapy uses high energy photons/electrons to kill tumor cells and shrink tumors. Delivering a boost radiation treatment before surgery when doctors can still visualize the tumor on imaging may help to better target the tumor and decrease the volume of normal irradi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/20/2023
Locations: Clara Maass Medical Center, Belleville, New Jersey
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Recruiting
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/19/2023
Locations: The Valley Hospital-Luckow Pavilion, Paramus, New Jersey
Conditions: Cancer Metastatic, Metastatic Solid Tumor
A Study of DF6002 Alone and in Combination With Nivolumab
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2023
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Solid Tumors
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. Howe... Read More
Gender:
All
Ages:
All
Trial Updated:
04/18/2023
Locations: Atlantic Health System, Morristown, New Jersey
Conditions: Spinal Muscular Atrophy (SMA)